Angioplasty Balloons Market is expected to reach US$ 3.60 billion by 2030

According to our latest study on "Angioplasty Balloons Market Forecast to 2030 – Global Analysis – by Type, Application, and End User," the angioplasty balloons market size was valued at US$ 2.71 billion in 2022 and is expected to reach US$ 3.60 billion by 2030. It is estimated to register a CAGR of 3.6% from 2022 to 2030. The increasing prevalence of cardiovascular diseases and the rising use of percutaneous coronary intervention (PCI) are the key factors driving the market. Moreover, the angioplasty balloons market trends include continued advancements in angioplasty balloon technologies.  

There is still tremendous diversity in lesion detection by colonoscopy, but early detection of colorectal cancer (CRC) in gastroenterology by national screening offers patients the highest chance of overall survival. When assessing the screening for colorectal cancer, the adenoma detection rate (ADR) is considered the gold standard. Advances in imaging technology, withdrawal technique, endoscopist motivation, and understanding, as well as social and environmental factors, contribute to improved ADR.

Unprotected left main stem artery disease (also known as unprotected left main stem percutaneous intervention) is being increasingly treated with PCI. The primary treatment for coronary heart disease is PCI. Approximately 97,000 PCI procedures were performed worldwide in 2021. In China, 1.04 million PCI procedures were completed in 2019. PCI is one of the procedures for treating chronic total occlusions (CTO), resulting in successful recanalization of CTO. Balloon angioplasty is part of the PCI, in which a small balloon on a long, thin tube is used to flatten or compress the plaque against the artery wall. CTO PCIs represent 4% of all PCIs for stable angina in the US. As per the National Heart, Lung, and Blood Institute, CTOs are found in approximately one-third of patients undergoing angiography. According to Eurostat, in 2020, 138,000 cardiac bypass surgeries and 1 million transluminal coronary angioplasty surgeries were performed.

With the advantage of not leaving metal implants in place and avoiding potential long-term side effects, drug-coated balloons can be an appealing therapeutic option. These devices enable local drug delivery of the antiproliferative agents directly into the coronary artery wall following a single balloon inflation. It is possible to manage CTO with a DCB-only technique and anterograde lumen-to-lumen. Therefore, the growing use of PCI is fueling the angioplasty balloons market growth.

Market Segmentation:

The angioplasty balloons market analysis has been carried out by considering the following segments: type, application, and end user.

Angioplasty Balloons Market, by Type:

Based on type, the market is segmented into normal balloons, drug eluting balloons, cutting balloons, and scoring balloons. The normal balloons segment held the largest angioplasty balloons market share in 2022. However, the drug eluting balloons segment is anticipated to register the highest CAGR during 2022–2030. In endovascular therapy, drug-coated balloons (DCB), primarily paclitaxel-coated balloons, are being utilized more frequently to improve the low patency results of angioplasty. When addressing hemodialysis access dysfunction, the use of drug-eluting balloons might, in the short run, require less reintervention and associated healthcare costs than simple balloon angioplasty.  

Angioplasty Balloons Market, by End User:

By end user, the angioplasty balloons market is segmented into hospitals, ambulatory surgery centers, and others. The hospitals segment held the largest angioplasty balloons market share in 2022 and is anticipated to register the highest CAGR during 2022–2030, owing to the minimum hospital stay requirements and the availability of advanced services. In addition, treatments performed in ambulatory surgery centers are cost-effective, which helps cut down on total medical costs. All these factors are contributing to the growth of the ambulatory surgery centers segment.

Angioplasty Balloons Market, by Geography:

The geographic scope of the angioplasty balloons market report entails North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). The angioplasty balloons market growth in North America is fueled by the increasing burden of the aging population, rising number of product launches, and growing activities of R&D to develop advanced angioplasty balloons. Asia Pacific is expected to register the highest CAGR during the forecast period. The region occupies a significant position in the global angioplasty balloons market and is expected to demonstrate a promising growth trajectory during the forecast period. The driving factors for the growth of the market are the increasing prevalence of cardiovascular diseases, growing aging population, improving healthcare infrastructure, and rising awareness about minimally invasive procedures.

The US accounted for the significant North American angioplasty balloons market share owing to increasing cases of heart disease. According to the American Heart Association, due to cardiovascular diseases, one person dies every 34 seconds in the US. In 2020, ~697,000 people in the US died from heart disease, i.e., one in every five deaths. In March 2023, in the US, SIS Medical AG introduced the OPN NC PTCA Dilatation Catheter with TWIN-Wall technology. By offering great performance and safety along with success rates where other balloons fail, the product expands therapy possibilities. The OPN NC catheter features a TWIN-Wall design, which offers a super-high pressure resistance with a rated burst pressure of 35 atm with a very low compliance. Moreover, in December 2022, GIE Medical launched two clinical trials in the country to investigate the use of ProTractX3 TTS DCB, its multi-stage drug-coated balloon (DCB) technology, in esophageal and bowel strictures. The dubbed PAclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture–Esophagus (PATENT-E) has been designed to assess the efficiency and safety of the DCB technology to treat benign oesophagal strictures.

The angioplasty balloons market report emphasizes prominent players operating in the market. The players include Abbott, Boston Scientific Corporation, Cardinal Health, Cook Medical, C. R. Bard Inc., ENDOCOR GmbH, Medtronic, Spectranetics, BIOTRONIK, and Terumo Medical Corporation.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com